EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtÜbersichtsarbeit

Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality

Faizan Ahmed, Faseeh Haider, Ramsha Ali, Muhammad Arham iD, Najam Gohar, Ayesha Batool, Sara Sharif, Muhammad Huzaifa Ahmed Khan, Zuha Tariq iD, Syeda Simrah Shah, Aman Ullah, Ahsan Alam iD und 8 weitere

Catheterization and Cardiovascular Interventions · 2026

DOI: 10.1002/ccd.70363 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Faizan Ahmed und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, New Jersey, USA. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy, Coronary Artery Disease. Die Arbeit nennt 49 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Current ESC/EACTS guidelines recommend standard‐duration dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). However, the subsequent transition to either extended DAPT or single antiplatelet therapy (SAPT) remains debated due to limited comparative outcome data. This Bayesian meta‐analysis and meta‐regression evaluate the clinical safety of DAPT versus SAPT, and the impact of potential confounders on all‐cause mortality.

Methods

Following PRISMA guidelines, a systematic search of PubMed, Embase, Cochrane Library, ScienceDirect, and Scopus was conducted till April 2025 to identify randomized clinical trials (RCTs) and cohort studies. Primary outcomes were all‐cause mortality and bleeding events. Bayesian random‐effects meta‐analysis was performed using the brms package in R with Markov Chain Monte Carlo sampling and weakly informative priors. Bayesian meta‐regression of log‐transformed odds ratios (OR) assessed associations with relevant covariates.

Results

Fourteen studies (9 RCTs and 5 cohort studies) comprising 56,572 patients were included. Compared with SAPT, DAPT was associated with increased all‐cause mortality (OR 1.25; 95% credible interval [CrI], 1.04–1.51; posterior probability of harm, Pr[OR > 1] = 84%). DAPT also increased the risk of net adverse clinical events [NACE] (OR, 1.29; 95% CrI, 1.08–1.53), minor bleeding (OR, 1.60; 95% CrI, 1.10–2.33), major bleeding (OR, 1.70; 95% CrI, 1.30–2.23), and BARC 2–5 bleeding (OR, 1.78; 95% CrI, 1.40–2.26) with Pr [OR > 1] >90% for all outcomes. No significant differences were observed in cardiac death, cardiovascular mortality, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), stent thrombosis, or stroke. Meta‐regression revealed that higher baseline odds of dyslipidemia (−0.89), hypertension (−1.19), prior MI (−0.94), and previous revascularization (−0.30) were associated with greater mortality benefit from DAPT. However, in the DAPT cohort, increased odds of adverse events, including cardiac death (0.41), MACCE (0.55), stroke (0.60), MI (0.29), and NACE (0.98), were significantly associated with higher all‐cause mortality.

Conclusion

Extended DAPT is associated with a higher all‐cause mortality, bleeding events, and NACE. While DAPT may benefit high‐risk populations, the increased odds of adverse events are significantly associated with mortality, warranting that it be carefully considered and monitored in post‐PCI patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsPercutaneous Coronary InterventionDual Anti-Platelet TherapyCoronary Artery DiseaseHumansBayes TheoremHemorrhageRisk AssessmentRisk FactorsTreatment OutcomeTime FactorsAgedMaleFemaleDrug Administration ScheduleMiddle AgedCause of Death

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, New Jersey, USA.
  • Allama Iqbal Medical College, Lahore, Pakistan.
  • Peoples University of Medical & Health Sciences, Nawabshah, Pakistan.
  • Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan.
  • Ameer-ud-Din Medical College, Lahore, Pakistan.
  • King Edward Medical University, Lahore, Pakistan.

ORCID-Profile: Muhammad Arham, Zuha Tariq, Ahsan Alam, Muhammad Usman, Tehmasp Rehman Mirza, Ameer Haider Cheema

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Ahmed, F., Haider, F., Ali, R., Arham, M., Gohar, N., Batool, A., Sharif, S., Khan, M. H. A., Tariq, Z., Shah, S. S., Ullah, A., Alam, A., Hamdani, S. S. Q., Usman, M., Mirza, T. R., Sattar, Y., Patel, S., Almendral, J., Cheema, A. H., & Alenezi, F. (2026). Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70363

Vancouver

Ahmed F, Haider F, Ali R, Arham M, Gohar N, Batool A, et al. Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70363

BibTeX
@article{Ahmed2026,
  author = {Ahmed, Faizan and Haider, Faseeh and Ali, Ramsha and Arham, Muhammad and Gohar, Najam and Batool, Ayesha and Sharif, Sara and Khan, Muhammad Huzaifa Ahmed and Tariq, Zuha and Shah, Syeda Simrah and Ullah, Aman and Alam, Ahsan and Hamdani, Syed Shah Qasim and Usman, Muhammad and Mirza, Tehmasp Rehman and Sattar, Yasar and Patel, Swapnil and Almendral, Jesus and Cheema, Ameer Haider and Alenezi, Fawaz},
  title = {Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70363}
}
Kostenlos starten →